White House drops Heidi Overton as FDA chief nominee after GOP senators withhold support
WASHINGTON, DC: The White House on Tuesday, November 17, withdrew Dr. Heidi Overton's nomination to lead the Food and Drug Administration (FDA), abandoning her confirmation bid just a day before a Senate committee was scheduled to vote on whether to advance her appointment.
The decision followed weeks of resistance and uncertainty among Republican senators over her qualifications, scientific independence and positions on abortion and vaccines. The move leaves the FDA without a permanent commissioner.
White House drops Heidi Overton's FDA nomination after GOP senators raise concerns
A White House official confirmed the decision in an interview with Axios, which first reported the withdrawal. Overton, a preventive medicine physician and White House domestic policy official, was nominated by President Donald Trump in August. She previously served as chief policy officer at the conservative America First Policy Institute and has worked for Trump and organizations aligned with his agenda.

Overton's nomination faced bipartisan questions during the confirmation process, particularly over whether she would be willing to challenge the administration on scientific and public health matters. Republican Senator Bill Cassidy, chairman of the Senate Health, Education, Labor and Pensions Committee, had also raised concerns about her lack of managerial experience and ability to lead the agency.
Cassidy had questioned Overton's support for Trump's proposal to separate combination vaccines, including the measles, mumps and rubella vaccine, describing that position as "almost disqualifying". During her September confirmation hearing, the Louisiana lawmaker pressed her on whether she would maintain scientific independence from Trump and Health Secretary Robert F Kennedy Jr, a longtime vaccine critic.

Other Republican senators had also withheld commitments to support her nomination. Senator Susan Collins said last week that she was undecided and needed "to get some answers on various things.” Senator Lisa Murkowski had questioned Overton about political pressure surrounding access to mifepristone and criticized her for not taking a clear position on the issue.
To advance from the 21-member committee, Overton needed the support of at least 11 senators. With Democrats holding 11 seats, she would have needed Republican backing to secure a favorable committee vote and proceed to consideration by the full Senate.
Bill Cassidy links Heidi Overton's withdrawal to abortion policy dispute
Following the nomination withdrawal, Cassidy criticized the administration, suggesting Overton could have secured confirmation if the dispute over abortion policy had not emerged.
Tonight, the White House abandoned a viable confirmation path for Dr. Overton. The WH said that this was because she did not have the votes to pass. This was odd as I was having productive conversations with members. I believe she would have had the votes to pass out of committee and pass the full Senate. My conversations with her convinced me she would follow the science and push back against decisions that put Americans’ health at risk. The last issue was that pro-life Senators sought final assurances from the Administration regarding the Administration’s commitment to life issues. The Administration withdrew Dr. Overton rather than make such commitments. Unfortunately, with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats.
— U.S. Senator Bill Cassidy, M.D. (@SenBillCassidy) November 18, 2026
"Tonight, the White House abandoned a viable confirmation path for Dr. Overton," Cassidy wrote on X. "My conversations with her convinced me she would follow the science and push back against decisions that put Americans' health at risk."
The senator also shared a longer statement explaining his position and claimed that the final obstacle involved assurances sought by anti-abortion Republican senators.
Heidi Overton's position on abortion and mifepristone

Overton has praised the Supreme Court's decision to overturn Roe v Wade and advocated strict restrictions on medication abortion.
In a 2023 policy brief for the America First Policy Institute, she called for tighter regulation of mifepristone, criticized federal policies allowing abortion pills to be mailed and argued that abortion "is corrosive to children, women, and society broadly".